Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Oct 19 2018

• By Mandy Jackson, Joseph Haas, and Jessica Merrill

Business report

Related Content

Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie

Sep 24 2018

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor

Sep 29 2018

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Sep 11 2018

"Impressive" HbA1c And Weight Reductions Spur Phase III Plans For Lilly's Dual Incretin Agonist

Oct 04 2018

Eight Things To Know From Novartis' Third Quarter Call

Oct 18 2018

Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label

Oct 09 2018

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars

Oct 17 2018

Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground

Feb 07 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth

Jul 25 2018

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical

Jul 26 2018

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Jul 27 2018

Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Feb 07 2018

Related Companies

Bristol Myers Squibb Company

Biogen, Inc.

Eisai Co., Ltd.

Samsung Bioepis Co., Ltd.

AbbVie Inc.

Novartis AG

Gilead Sciences, Inc.

Eli Lilly and Company

Novo Nordisk A/S

Kite Pharma, Inc.

Additional Topics

Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window